Replimune’s RP1 is based on a genetically engineered herpes simplex virus intended to stimulate an anti-tumour immune response.

Early data show the cancer drug mocertatug rezetecan (Mo‑Rez) delivering response rates above 60% in patients with ovarian ...

The Japanese pharma is currently investigating mezagitamab’s potential in two late-stage autoimmune programmes.

Mortgage rates are based on movement in the bond market and although bonds experienced some volatility in response to Iran ...

Early survival results from the first stage of a phase 3 study suggest that gotistobart, a new antibody associated with anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), has potential as a ...

The Cleveland Federal Reserve President on Wednesday predicted that interest rates may stay where they’re at for a “good ...

In a controlled trial, volunteers showed significant changes in inflammatory markers, heart rate and blood pressure after one ...

Apollo reports five effective sales sequences for higher response rates, emphasizing personalization and timing to boost ...

MSC Cruises will raise its Hotel Service Charge gratuity rates for Caribbean and Alaska sailings beginning May 11.

Sofetabart mipitecan (LY4170156), an investigational folate receptor alpha (FRα)-targeted antibody-drug conjugate (ADC), elicited strong antitumor activity in patients with recurrent ...

Axitinib combined with octreotide long-acting release (LAR) significantly improved progression-free survival (PFS) per blinded independent central review (BICR) and objective response rate in patients ...